From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...

A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...

Important adverse events included infusion-related and hypersensitivity reactions in 25 of 306 immunocompromised participants (8.2%) who received pemivibart and anaphylaxis in 4 of 623 participants (0 ...

Monoclonal antibodies target specific disease molecules. They can help treat cancer, autoimmune disorders, and infectious diseases. Discover what you should know about this therapy. Monoclonal ...

The FDA has authorized a new treatment that may help immunocompromised people be protected from COVID-19. The treatment is a monoclonal antibody infusion that is expected to be available this April.

An antibody infusion therapy designed to help coronavirus patients recover faster may actually prevent people from getting the virus. A new clinical trial conducted by the University of North Carolina ...